| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.201001-0077OC |
| P698 | PubMed publication ID | 20442432 |
| P2093 | author name string | Armand Van Deun | |
| Hans L Rieder | |||
| Md Abdul Hamid Salim | |||
| Pankaj Kumar Das | |||
| Paul Daru | |||
| Aung Kya Jai Maug | |||
| Mihir Ranjan Sarker | |||
| P2860 | cites work | Multidrug-resistant tuberculosis management in resource-limited settings | Q35805726 |
| Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo | Q36047567 | ||
| Turning liabilities into resources: informal village doctors and tuberculosis control in Bangladesh | Q37063529 | ||
| Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis | Q37216059 | ||
| HIV/AIDS in Bangladesh: a national surveillance. | Q37344643 | ||
| Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods | Q39695137 | ||
| Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006 | Q28472337 | ||
| Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis | Q28476110 | ||
| Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis | Q34952765 | ||
| Fourth-generation fluoroquinolones in tuberculosis | Q34974217 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| multiple drug resistance | Q643839 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 684-692 | |
| P577 | publication date | 2010-05-04 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis | |
| P478 | volume | 182 |
| Q38514218 | 'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility |
| Q37089599 | A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant Tuberculosis |
| Q57026722 | A new era for treatment of drug-resistant tuberculosis |
| Q21131083 | A new strategy to fight antimicrobial resistance: the revival of old antibiotics |
| Q40220575 | AJRCCM: 100-Year Anniversary. Focus on Tuberculosis |
| Q39094119 | Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. |
| Q35673425 | Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. |
| Q38102921 | Advances in the development of new tuberculosis drugs and treatment regimens |
| Q38837774 | Adverse effects of oral second-line antituberculosis drugs in children. |
| Q39780875 | Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB. |
| Q28487938 | Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality |
| Q38885365 | An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis |
| Q95411893 | An update on multidrug-resistant tuberculosis |
| Q38533435 | Antituberculosis drugs in children |
| Q26829101 | Antituberculosis therapy for 2012 and beyond |
| Q30415943 | Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania |
| Q64936595 | Application of serial tests for Mycobacterium tuberculosis detection to active lung tuberculosis cases in Indonesia. |
| Q37306561 | Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. |
| Q28552001 | Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study |
| Q41521818 | Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline |
| Q41518869 | Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis |
| Q38386950 | Bedaquiline for the treatment of drug-resistant tuberculosis |
| Q28555235 | Bibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015) |
| Q82898085 | Can Some Patients with Multidrug-Resistant Tuberculosis Be Cured with Shorter Duration of Chemotherapy? |
| Q38043978 | Caring for children with drug-resistant tuberculosis: practice-based recommendations. |
| Q47244908 | Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children |
| Q38095593 | Challenges to the global control of tuberculosis |
| Q33760793 | Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis |
| Q36888058 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. |
| Q35363843 | Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation |
| Q40280093 | Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections |
| Q50453280 | Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China |
| Q39231486 | Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. |
| Q57945933 | Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche |
| Q34331039 | Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study |
| Q35031351 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis |
| Q34633213 | Clofazimine: current status and future prospects |
| Q46241770 | Common errors in multidrug-resistant tuberculosis management |
| Q53041364 | Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis |
| Q35953915 | Community-based treatment of multidrug-resistant tuberculosis: early experience and results from Western Kenya. |
| Q36439105 | Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis |
| Q92127169 | Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis |
| Q36794791 | Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis |
| Q28544800 | Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK |
| Q38849126 | Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis |
| Q50508187 | Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India |
| Q57940600 | Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens |
| Q61447856 | Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/I |
| Q37643781 | Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis |
| Q35693044 | Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study |
| Q30419537 | Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action |
| Q89982211 | Drug effect of clofazimine on persisters explain an unexpected increase in bacterial load from patients |
| Q37619123 | Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time |
| Q61766644 | Drug-Resistant Tuberculosis |
| Q36924283 | Drug-Resistant Tuberculosis: Challenges and Progress |
| Q39395839 | Drug-Resistant tuberculosis - primary transmission and management |
| Q33801345 | Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis |
| Q34775244 | Drug-resistant tuberculosis control in South Africa: scientific advances and health system strengthening are complementary |
| Q40959612 | Drug-resistant tuberculosis. Epidemiology, diagnostics and therapy |
| Q58790087 | Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment |
| Q30428762 | Drug-resistant tuberculosis: time for visionary political leadership |
| Q37356114 | Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol |
| Q40419289 | Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis |
| Q28552524 | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease |
| Q33810454 | Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial |
| Q64126139 | Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016 |
| Q54005515 | Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. |
| Q26771997 | Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? |
| Q58321647 | Encouraging News for Multidrug-resistant Tuberculosis Treatment |
| Q36076037 | Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City |
| Q40377338 | Estimated generic prices for novel treatments for drug-resistant tuberculosis |
| Q82315364 | Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis |
| Q34184543 | Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. |
| Q35712475 | Evidence for the presence of clofazimine and its distribution in the healthy mouse brain. |
| Q61807769 | Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic |
| Q38221214 | Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis |
| Q28547703 | High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa |
| Q39779537 | High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens. |
| Q39463170 | High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013. |
| Q64091498 | How Can Operational Research Help to Eliminate Tuberculosis in the Asia Pacific Region? |
| Q35962789 | Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis |
| Q53686602 | Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. |
| Q35008349 | Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death |
| Q64973182 | In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China. |
| Q88764112 | In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis |
| Q91726514 | In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis |
| Q36050648 | Increasing access to the MDR-TB surveillance programme through a collaborative model in western Kenya |
| Q100992238 | Infectiologie respiratoire: Respiratory infectious diseases |
| Q92084477 | Inhaled Antibiotics for Mycobacterial Lung Disease |
| Q40195955 | Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. |
| Q99633747 | Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes |
| Q38053000 | Is repositioning of drugs a viable alternative in the treatment of tuberculosis? |
| Q49830844 | Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations |
| Q33820505 | Isoniazid-resistant tuberculosis: a cause for concern? |
| Q45922051 | Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting. |
| Q64063419 | Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape |
| Q40522723 | Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. |
| Q33798468 | Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas |
| Q36734349 | Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. |
| Q34455442 | Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review |
| Q38040155 | Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012 |
| Q35990636 | Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing? |
| Q26765394 | Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings |
| Q42715629 | Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement |
| Q38995175 | Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline |
| Q26801601 | Medical Management of Drug-Resistant Tuberculosis |
| Q38182982 | Medical treatment of pulmonary multidrug-resistant tuberculosis |
| Q35859964 | Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis |
| Q35105344 | Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs |
| Q36195588 | Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan |
| Q35990643 | Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes |
| Q83608152 | Multi-resistant tuberculosis |
| Q28482730 | Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients |
| Q82589218 | Multidrug resistant tuberculosis -- its extent, hazard and possible solutions |
| Q38445649 | Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis |
| Q43200280 | Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen |
| Q38216995 | Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. |
| Q91802511 | Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family |
| Q92236107 | Multidrug-resistant tuberculosis - Authors' reply |
| Q35130346 | Multidrug-resistant tuberculosis in Europe, 2010-2011 |
| Q55100566 | Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. |
| Q37120065 | Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis |
| Q47446710 | Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance |
| Q92857480 | Mycobacterium tuberculosis cysteine biosynthesis genes mec+-cysO-cysM confer resistance to clofazimine |
| Q26741138 | New Antituberculosis Drugs: From Clinical Trial to Programmatic Use |
| Q39010772 | New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. |
| Q53206282 | New drugs for treatment of tuberculosis |
| Q36018409 | New drugs to treat tuberculosis |
| Q38024041 | New treatment options for multidrug-resistant tuberculosis. |
| Q91807571 | New tuberculosis drug targets, their inhibitors, and potential therapeutic impact |
| Q43694821 | New tuberculosis drugs in resistant and multiresistant tuberculosis |
| Q38210363 | Novel diagnostics and therapeutics for drug-resistant tuberculosis |
| Q52648707 | Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis |
| Q36461593 | Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis |
| Q92003927 | Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries |
| Q37961280 | Paediatric use of second-line anti-tuberculosis agents: a review |
| Q40168276 | Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa |
| Q38617675 | Personalized medicine for patients with MDR-TB. |
| Q36094215 | Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines |
| Q35607808 | Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis |
| Q46271797 | Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs |
| Q54245604 | Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity |
| Q30411475 | Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis |
| Q49571536 | Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence |
| Q91700534 | Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling |
| Q42368090 | Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients |
| Q39503800 | Prevalence of pulmonary tuberculosis among prison inmates: A cross-sectional survey at the Correctional and Detention Facility of Abidjan, Côte d'Ivoire |
| Q64360344 | Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study |
| Q36647864 | Preventing Nosocomial MDR TB Transmission in sub Saharan Africa: Where Are We at? |
| Q37398037 | Principles for designing future regimens for multidrug-resistant tuberculosis. |
| Q28552438 | Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda |
| Q36364095 | Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis |
| Q48193600 | Quantitative analysis of clofazimine (Lamprene®), an antileprosy agent, in human dried blood spots using liquid chromatography-tandem mass spectrometry. |
| Q28543642 | Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice |
| Q40829224 | RAIRS2 a new expert system for diagnosing tuberculosis with real-world tournament selection mechanism inside artificial immune recognition system. |
| Q42330724 | Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome |
| Q36149564 | Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF? |
| Q44003595 | Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis |
| Q28085210 | Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children |
| Q52575510 | Recent advances in tuberculosis diagnostics in resource-limited settings |
| Q30360811 | Recent advances in tuberculosis: New drugs and treatment regimens. |
| Q40076101 | Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? |
| Q90044391 | Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis |
| Q53732591 | Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria |
| Q47429675 | Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis. |
| Q34524569 | Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review |
| Q27011672 | Rising to the challenge: new therapies for tuberculosis |
| Q37203798 | Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates |
| Q37516784 | Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies |
| Q39751186 | Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea. |
| Q92282200 | Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence |
| Q26765369 | Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials |
| Q49513327 | Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope |
| Q84481041 | Shorter treatment duration for selected patients with multidrug-resistant tuberculosis: Table 1– |
| Q64058350 | Simultaneous determination of the potent anti-tuberculosis regimen-Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC-MS/MS method coupled with 96-well format plate |
| Q95854011 | Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety as Potential Antimycobacterial Agents |
| Q39398946 | Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. |
| Q36018542 | Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis |
| Q28477317 | Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis |
| Q91315172 | Strategic investment in tuberculosis control in the Republic of Bulgaria |
| Q38094353 | Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. |
| Q46813086 | Target regimen profiles for treatment of tuberculosis: a WHO document. |
| Q64240244 | The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 |
| Q92610716 | The STREAM trial: missed opportunities and lessons for future clinical trials |
| Q41683618 | The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis |
| Q39262652 | The changing landscape in drug resistant-tuberculosis: an analysis of recent advances |
| Q28551772 | The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review |
| Q36180685 | The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance |
| Q30235074 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis |
| Q35815071 | The need to accelerate access to new drugs for multidrug-resistant tuberculosis |
| Q38676708 | The paradigm shift to end tuberculosis. Are we ready to assume the changes? |
| Q26765372 | The role of moxifloxacin in tuberculosis therapy |
| Q38933875 | The safety and tolerability of the second-line injectable antituberculosis drugs in children. |
| Q42357124 | The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? |
| Q50134159 | The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China |
| Q35718605 | Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in rural Bangladesh: lessons learnt |
| Q56889741 | Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis |
| Q36511908 | Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. |
| Q56398216 | Treatment of drug-resistant tuberculosis – Authors' reply |
| Q36825990 | Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection |
| Q94468653 | Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015 |
| Q92764929 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis |
| Q90184320 | Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data |
| Q57235679 | Tuberculosis |
| Q92572130 | Tuberculosis |
| Q90642892 | Tuberculosis and HIV-An Update on the "Cursed Duet" in Children |
| Q36211825 | Tuberculosis control in China: use of modelling to develop targets and policies |
| Q55179434 | Tuberculosis in South Asia: a tide in the affairs of men. |
| Q30248788 | Tuberculosis therapy for 2016 and beyond |
| Q38795742 | Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers |
| Q27021104 | Tuberculosis: epidemiology and control |
| Q52629914 | Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies |
| Q37181195 | Turning the respiratory flexibility of Mycobacterium tuberculosis against itself |
| Q30411703 | Understanding pharmacokinetics to improve tuberculosis treatment outcome |
| Q39427346 | Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India |
| Q37902000 | Update in tuberculosis and nontuberculous mycobacterial disease 2010. |
| Q33832822 | Use of GeneXpert Remnants for Drug Resistance Profiling and Molecular Epidemiology of Tuberculosis in Libreville, Gabon |
| Q60045628 | Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts |
| Q40237873 | Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro |
| Q26852253 | WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis |
| Q41658421 | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
| Q40633103 | WHO recommendations on shorter treatment of multidrug-resistant tuberculosis |
| Q38856343 | WHO strategies for the programmatic management of drug-resistant tuberculosis |
| Q37287719 | Weight gain and response to treatment for multidrug-resistant tuberculosis |
| Q56669499 | What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? |
| Q28066845 | What can we offer to 3 million MDRTB household contacts in 2016? |
| Q61817704 | What's Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis |
| Q36957270 | World Health Organization Group 5 Drugs for the Treatment of Drug-Resistant Tuberculosis: Unclear Efficacy or Untapped Potential? |
| Q30377488 | World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. |
| Q92358370 | [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador] |
Search more.